Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | MAPT | P10636 | 8/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2644838 | 0.92 | MEN1 (0.55) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL2643916 | 0.91 | MEN1 (0.59) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL2643643 | 0.91 | MEN1 (0.54) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL3421633 | 0.88 | ALDH1A1 (0.62) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL2643615 | 0.88 | MEN1 (0.53) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL2661333 | 0.86 | ADORA1 (0.53) | MAPTKDM4E | |
| SCHEMBL4693140 | 0.86 | MEN1 (0.49) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL14408985 | 0.83 | GCGR (0.58) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL2644393 | 0.83 | L3MBTL1 (0.67) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL13739786 | 0.83 | MEN1 (0.55) | MEN1KMT2AALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138529-B2 | Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-11-21 | — | — | US | claimed |
| EP-1620425-A1 | SUBSTITUTED 3-CYANOTHIOPHENE ACETAMIDES AS GLUCAGON RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-01 | — | — | EP | claimed |
| WO-2004092156-A1 | SUBSTITUTED 3-CYANOTHIOPHENE ACETAMIDES AS GLUCAGON RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-28 | — | — | WO | claimed |
| US-20040209943-A1 | Novel substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | ERICKSON SHAWN DAVID (US) | 2004-10-21 | — | — | US | claimed |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | REMD Biotherapeutics, Inc | 2017-05-25 | — | — | US | disclosed |
| EP-1620425-B1 | SUBSTITUTED 3-CYANOTHIOPHENE ACETAMIDES AS GLUCAGON RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-12-24 | — | — | EP | disclosed |
| US-7138529-B2 | Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7138529-B2 | Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1620425-A1 | SUBSTITUTED 3-CYANOTHIOPHENE ACETAMIDES AS GLUCAGON RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004092156-A1 | SUBSTITUTED 3-CYANOTHIOPHENE ACETAMIDES AS GLUCAGON RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-28 | — | — | WO | disclosed |
| US-20040209943-A1 | Novel substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | ERICKSON SHAWN DAVID (US) | 2004-10-21 | — | — | US | disclosed |
| US-20040209943-A1 | Novel substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | ERICKSON SHAWN DAVID (US) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209943-A1 | Novel substituted 3-cyanothiophene acetamides as glucagon receptor antagonists | GLP1R, GCGR, GPR119 | MEN1 1036/4885KMT2A 3567/4885ALDH1A1 1214/4885 |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | GLP1R, GCGR, GIPR | MEN1 4200/4885KMT2A 2219/4885ALDH1A1 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.